-
Product Insights
NewNet Present Value Model: Entera Bio Ltd’s Teriparatide
Empower your strategies with our Net Present Value Model: Entera Bio Ltd's Teriparatide report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-219 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-219 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-219 in Metastatic Colorectal Cancer Drug Details: NT-219 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHRA-1904 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHRA-1904 in Pancreatic Cancer Drug Details: SHRA-1904 is under development for...
-
Product Insights
Hypoparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypoparathyroidism - Drugs In Development, 2023’, provides an overview of the Hypoparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Malabsorption Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Malabsorption Syndrome - Drugs In Development, 2023’, provides an overview of the Malabsorption Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malabsorption Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Short Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Short Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Short Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Growth Hormone Deficiency – Drugs In Development, 2023
Global Markets Direct’s, ‘Growth Hormone Deficiency - Drugs In Development, 2023’, provides an overview of the Growth Hormone Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Growth Hormone Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AU-314 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AU-314 in Breast Cancer Drug Details: AU-314 is under development for the treatment of solid...